|Bid||108.85 x 800|
|Ask||109.75 x 800|
|Day's Range||108.90 - 112.50|
|52 Week Range||58.03 - 133.74|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||147.40|
With Gilead Sciences, Inc. (NASDAQ: GILD )'s NASH setback, Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT )'s Ocaliva, which is being evaluated in a late-stage study for NASH with fibrosis, is taking the ...
Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.
Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPTView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for ICPT with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ICPT totaled $4.26 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...
Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) recently announced Jan. 7 that it expects to release top-line data from the interim analysis of the Phase 3 study dubbed "REGENERATE" during the ...
Investors need to pay close attention to Intercept Pharmaceuticals (ICPT) stock based on the movements in the options market lately.
Top-line data from the interim analysis of the Phase 3 REGENERATE trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis.
NEW YORK, Jan. 02, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.
The race is on in the pharmaceutical industry to develop drugs to treat a form of fatty liver disease called nonalcoholic steatohepatitis, also known as NASH. The U.S. is spending $5 billion annually in health-care costs related to the disease, which include chemotherapy, transplants, tests and hospitalizations, reports the Center for Disease Analysis. The National Institutes of Health estimates as many as 12 percent of U.S. adults have this disease, or 30 million people.
Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.
Mark Pruzanski has been the CEO of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) since 2002. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The one and a half month time period since the end of the […]
At a time when other social networking sites like Facebook (NASDAQ:FB) are struggling to figure out their place in the foreseeable future, Twitter (NYSE:TWTR) is enjoying the fact that it has just recently figured out what it is and how to sell itself. The pros are calling for sales growth of nearly 14% next year, though, which should drive the bottom line up to 89 cents per share of TWTR stock. The trading crowd hasn’t exactly priced Twitter shares like the growth machine it is.
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...